Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia Options Price in $280 Billion Earnings Swing 
Tesla Raises Cybertruck Prices by $5,000 in US 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Trump Buys SpaceX Shares After Record IPO 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Add as a preferred source on Google
LOS ANGELES, April 24, 2018 -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to announce it has entered into a $250,000 initial sales agreement with Vage Nigeria Ltd. (“Vage”), a brand support company specializing in product sourcing.
According to the terms of the agreement, Vage will pay a 50% deposit to ViaDerma upon completion of the registration of Vitastem with the National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria’s equivalent to the FDA. The registration process should be completed within 30 days. The balance of the order will be paid to ViaDerma upon delivery of the product in about 8-10 weeks.
Dr. Christopher Otiko, President of ViaDerma, stated “We are very pleased to be working together with Vage and their CEO, Kunle Craig to provide Vitastem to the people of Nigeria. This is only the first of many orders we expect to receive from Vage going forward.”
Kunle Craig, CEO of Vage Nigeria Ltd., commented, “Vitastem is a wonderful ointment that has exceeded all expectations during our testing. The feedback received and the results we have seen have so far been 100% positive. Infections have cleared up in just 3 days, and leg burns have seen significant improvement within 24 hours of application. I’ve witnessed firsthand the positive results brought upon by Vitastem in wound and skin treatment, and I have become a firm believer in this product. From what I have observed, Vitastem is a revolutionary medication.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC:VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: www.viadermalicensing.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: [email protected]
Phone: 310-374-6111
